Bayer’s BlueRock Reports the P-I Study Data for Bemdaneprocel (BRT-DA01) Stem Cell Therapy to Treat Parkinson’s Disease
Shots:
- The P-I study evaluates the safety & tolerability of bemdaneprocel transplantation in patients (n=12) with Parkinson's disease 1yr. post-transplant as the 1EPs & evidence of transplanted cell survival & motor effects at 1 & 2yrs post-transplant as 2EPs
- The results depicted that bemdaneprocel was well-tolerated & the 2EPs of the study showed the efficacy of transplantation & evidence of cell survival & engraftment in the brain for 1yr. Patient enrolment in the P-II study is expected to initiate by H1’24
- Bemdaneprocel consists of dopamine-producing neurons derived from pluripotent stem cells & is surgically implanted into the brain upon which it reforms the neural network destroyed in the diseased individual
Ref: Bayer | Image: Bayer
Related News:- Bayer’s Kerendia (finerenone) Receives NICE Recommendation for Chronic Kidney Disease Associated with Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
